Hydrocortisone tablets: suspected excessive and unfair pricing

The CMA is investigating alleged excessive and unfair prices with respect to hydrocortisone tablets under Chapter II CA98 and Article 102 TFEU.

Case timetable

Date Action
September 2017 to June 2018 (estimate) Consideration of parties’ written and oral representations on the statement of objections; further evidence gathering and analysis; issue of draft penalty statements and letter of facts; receipt and consideration of parties’ representations on letters of facts and draft penalty statements
August 2017 Statement of objections issued to new addressees
March to May 2017 Receipt of written and oral representations on the statement of objections
December 2016 Statement of objections issued
September to December 2016 Further information gathering and analysis of information requests
September 2016 Decision to continue with the investigation
August 2016 to September 2016 Investigation and analysis including further information requests and stakeholder meetings
March to July 2016 Initial investigation: information gathering, including issuance of formal or informal information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
March 2016 Investigation opened

Statement of objections issued to new parties

9 August 2017: The CMA issued a statement of objections to Intas Pharmaceuticals Limited and Accord Healthcare Limited, which acquired Actavis UK in January 2017, alleging that Actavis UK has breached and continues to breach UK and EU competition law by charging excessive and unfair prices in relation to the supply of hydrocortisone tablets in the UK and proposing to find them jointly and severally liable for the alleged infringements from their period of ownership.

Statement of objections

16 December 2016: The CMA issued a statement of objections alleging that Actavis UK has breached UK and EU competition law by charging excessive and unfair prices in relation to the supply of hydrocortisone in the UK.

Notes

  • The investigation is under Chapter II of the Competition Act 1998 (CA98) and Article 102 of the Treaty on the Functioning of the European Union (TFEU).
  • No conclusion should be drawn that there has been an infringement of competition law at this stage and the recipients of the statement of objections will now have an opportunity to respond to the allegations.
  • The CMA will consider any representations it receives before any decision is taken as to whether competition law has in fact been infringed.
  • Further detail of the CMA’s procedures in Competition Act 1998 cases is available here: CMA’s procedures in Competition Act 1998 cases.
  • Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.

Contacts

Principal Case Officer

Jane Howe (0203 738 6169, jane.howe@cma.gsi.gov.uk)

Project Director and Senior Responsible Officer

Andrew Groves (0203 738 6927, andrew.groves@cma.gsi.gov.uk)

Published 8 March 2016
Last updated 23 February 2018 + show all updates
  1. Case timetable updated.
  2. Statement of objections issued to new parties.
  3. Statement of objections issued.
  4. Timetable updated.
  5. First published.